Research shows that the drug Imatinib, usually prescribed for Leukemia and gastric cancer, halves mortality and shortens the stay of Covid patients at the ICU by a week. Imatinib is especially effective in the 20 percent most ill Covid patients. However, further research is needed. Follow-up studies will be done by Amsterdam OLVG, the Erasmus Medical Center, the Dijklander Hospital and by the World Health Organisation in the Remapcap study.
Read more (in Dutch)
For IXA -HvA and HvA Venture Centre 2024 started positive with their partnership in full swing. It is a milestone in the mission to support students from all AUAS faculties in developing their entrepreneurial competences. The Venture Centre is dedicated to nurturing the entrepreneurial spirit within AUAS student community. Through different initiatives like the 10K […]News
Berno Bucker will step into the role of interim director of Demonstrator Lab VU. He’s succeeding Linda van de Burgwal, who was director for the past two years. Berno is no stranger to the Demonstrator Lab, having launched his own start-up there six years ago and spending the last four years coaching Demonstrator Lab projects. […]News
To develop an optical spectroscopy device for sizing molecules and nanoparticlesNews